新型抗癫痫药-卢非酰胺（Rufinamid）

Rufinamide is a triazole derivative, and its specific mechanism of action is unclear. Research suggests that it is related to prolonging the inactivation time of Na+ channels. It was launched in Europe in 2007 and in the United States in 2008 based on a phase III clinical trial. It is currently mainly used for the treatment of Lennox-Gastant syndrome in children over 1 year old, especially the treatment of tonic or atonic seizures.

In a phase III randomized double-blind placebo-controlled clinical trial involving 356 patients with refractory partial epilepsy, the seizure frequency of the lucamide group was reduced by 23.25%, which was significantly lower than that of the placebo group (9.8%); the rate of seizure reduction of ≥50% in the treatment group (32.5%) was significantly higher than that of the placebo group (14.3%). The adverse reactions caused by rufinamide are similar to those of other AEDs, but it should be noted that rufinamide can cause a shortening of the Q-T interval of the electrocardiogram. The latest phase III clinical trial shows that reducing the initial dose of rufinamide and slowly increasing the dose can effectively reduce the incidence of adverse reactions without affecting the efficacy.

Starting daily dose of rufinamide: 400-800 mg per day, taken in two divided doses. Increase by 400-800mg every other day until you reach the maximum dose of 3200mg/day (in two divided doses). Common side effects are headache, dizziness, fatigue, drowsiness and nausea. If you are currently using rufinamide, the editor here recommends that patients must take the correct medication according to the doctor's instructions. Some patients always think that simply increasing the dosage of the drug can improve the effect of the drug itself, and they also think that simply reducing the dosage of the drug can reduce the occurrence of side effects. However, this is not actually the case. If the dosage of the drug is changed privately, it may cause more adverse reactions, so do not use the drug blindly.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.